How Robust is the Cell & Gene Therapies Industry? Investment Funding and Commercial Returns

Chair

Peter Olagunju, Board of Directors, March Biosciences

3pm Presentation

Asthika Goonewardene, Managing Director, Truist Securities

Patrick Rivers, Managing Director & Head of Research, Aquilo Capital Management

3.15pm Presentation: Cell and Gene Therapy in 2024 – Surefire Strategies Regardless of Feast or Famine

• How macro trends (e.g., 2030 patent cliff, CMS drug pricing negotiations) will impact CGT
• Which funding, M&A, or clinical milestones are leading indicators for industry performance
• What key facility/technology, process, and personnel investments yield ROI at the lowest risk in both bull and bear markets

John Lee, Vice President, Cell Therapy, SK Pharmteco

3.30pm Panel Discussion joined by

Gregory Fiore, Former Chief Executive Officer, Exacis Biotherapeutics

Deana Mohr, Chief Executive Officer & Co-Founder, MUVON Therapeutics